Last reviewed · How we verify
Postop orphenadrine IV
Orphenadrine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce muscle spasms and provide analgesic effects.
Orphenadrine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce muscle spasms and provide analgesic effects. Used for Postoperative muscle spasm and pain relief, Acute musculoskeletal pain management.
At a glance
| Generic name | Postop orphenadrine IV |
|---|---|
| Also known as | Norflex |
| Sponsor | AdventHealth |
| Drug class | Anticholinergic agent / Muscle relaxant |
| Target | Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Orphenadrine acts as a competitive antagonist at muscarinic cholinergic receptors, which reduces acetylcholine-mediated muscle contraction and spasm. It also has local anesthetic and analgesic properties that contribute to pain relief. The IV formulation is used in acute postoperative settings for rapid onset of muscle relaxation and pain management.
Approved indications
- Postoperative muscle spasm and pain relief
- Acute musculoskeletal pain management
Common side effects
- Dry mouth
- Dizziness
- Tachycardia
- Urinary retention
- Blurred vision
Key clinical trials
- Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery (PHASE4)
- Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee (PHASE4)
- Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |